Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers May 29, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - May 29, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/22/17 - "Apparatus and Method for Cryogranulating a Pharmaceutical Composition" in Patent Application Approval Process (USPTO 20170119673)
By a News Reporter-Staff News Editor at Biotech Business Week A patent application by the inventors Amoro, Edwin; Vanackere, Karel; White, Michael A., filed on January 17, 2017, was made available online on May 11, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to
5/22/17 - "Penetrating Pharmaceutical Foam" in Patent Application Approval Process (USPTO 20170119665)
By a News Reporter-Staff News Editor at Pharma Business Week A patent application by the inventors Tamarkin, Dov; Friedman, Doron; Eini, Meir, filed on November 11, 2016, was made available online on May 11, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assigned
5/22/17 - 'Lust for profit takes over pharma industry'
The manufacturing cost of a new drug is from 1.2 to 1.8 billion dollars, and its manufacturing takes around 8-12 years following several processes, said University of Karachi ICCBS Director Professor Dr Muhammad Iqbal Choudhary here on Saturday. He was presenting his research paper at a three-day Fifth International Council for Life Sciences KIBGE.
5/22/17 - 21st century cures emerge as 20th century science matures
By a News Reporter-Staff News Editor at Clinical Trials Week WALTHAM, Mass., Most of the new drugs approved by the FDA since 2010 arose from basic scientific research that was initiated in the 1970 s or 1980 s, a new study from Bentley University has found. The PLOS One article, titled "Timelines of translational science: From technology initiati
5/22/17 - AC IMMUNE AND ESSEX BIO-TECHNOLOGY ANNOUNCE RESEARCH COLLABORATION FOR NEURODEGENERATIVE DISEASES AND NEUROINFLAMMATION
Powerful synergies in technologies and expertise Provides AC Immune with first R&D collaboration in Asia Lausanne, Switzerland, Hong Kong, China, May 22, 2017- AC Immune SA, a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, and Essex Bio-Technology Limited, specialized in biopharmaceutical drug developme
5/22/17 - Acadia Pharmaceuticals Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)] (May. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acadia Pharmaceuticals Inc. was posted on May 9, 2017. The SEC file number is 0001564590-17-009889.. A U.S. Securities and Exchange Commission filing
5/22/17 - Acadia Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (May. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acadia Pharmaceuticals Inc. was posted on May 9, 2017. The SEC file number is 0001415889-17-000711.. A U.S. Securities and Exchange Commission filing
5/22/17 - Acceleron Pharma Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)] (May. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on May 8, 2017. The SEC file number is 0001280600-17-000029.. A U.S. Securities and Exchange Commission filing is a
5/22/17 - Acceleron Pharma Inc. Files SEC Form 3, Initial Statement of Beneficial Ownership of Securities (May. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on May 8, 2017. The SEC file number is 0001179110-17-006834.. A U.S. Securities and Exchange Commission filing is a
5/22/17 - Acceleron Pharma Inc. Files SEC Form 8-K, Current Report (May. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acceleron Pharma Inc. was posted on May 8, 2017. The SEC file number is 0001280600-17-000026.. A U.S. Securities and Exchange Commission filing is a
5/22/17 - Acelrx Pharmaceuticals Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)] (May. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Acelrx Pharmaceuticals Inc. was posted on May 8, 2017. The SEC file number is 0001437749-17-008313.. A U.S. Securities and Exchange Commission filing
5/22/17 - Achaogen Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)] (May. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achaogen Inc. was posted on May 8, 2017. The SEC file number is 0001564590-17-009402.. A U.S. Securities and Exchange Commission filing is a formal d
5/22/17 - Achaogen Inc. Files SEC Form 8-K, Current Report (May. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achaogen Inc. was posted on May 8, 2017. The SEC file number is 0001564590-17-009370.. A U.S. Securities and Exchange Commission filing is a formal d
5/22/17 - Achaogen Inc. Files SEC Form S-3ASR, Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (May. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achaogen Inc. was posted on May 8, 2017. The SEC file number is 0001193125-17-162806.. A U.S. Securities and Exchange Commission filing is a formal d
5/22/17 - Achillion Pharmaceuticals Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)] (May. 4, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achillion Pharmaceuticals Inc. was posted on May 4, 2017. The SEC file number is 0001193125-17-158859.. A U.S. Securities and Exchange Commission fil
5/22/17 - Achillion Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (May. 4, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achillion Pharmaceuticals Inc. was posted on May 4, 2017. The SEC file number is 0001193125-17-158880.. A U.S. Securities and Exchange Commission fil
5/22/17 - Achillion Pharmaceuticals Inc. Files SEC Form DEFA14A, Additional Definitive Proxy Soliciting Materials And Rule 14(A)(12) Material (May. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Achillion Pharmaceuticals Inc. was posted on May 8, 2017. The SEC file number is 0001193125-17-162670.. A U.S. Securities and Exchange Commission fil
5/22/17 - Actelion provides an update on the progress towards launching Idorsia - Key results for pipeline assets to be developed by Idorsia
Actelion Pharmaceuticals Ltd/ Actelion provides an update on the progress towards launching Idorsia- Key results for pipeline assets to be developed by Idorsia. *Positive dose-finding results with ACT-132577- asset to progress to Phase 3 development in resistant hypertension* Positive safety study with cenerimod- asset to progress into larger Phase
5/22/17 - Actemra Approved for Certain Blood Vessel Inflammation
MONDAY, May 22, 2017 The injected drug Actemra has been approved by the U.S. Food and Drug Administration to treat adults with giant cell arteritis, an inflammation of the blood vessels. In a media release Monday, the FDA said this form of vasculitis mostly involves blood vessels of the head. For that reason, live vaccines should be avoided while
5/22/17 - Adamas Pharmaceuticals Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)] (May. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on May 9, 2017. The SEC file number is 0001628280-17-005234.. A U.S. Securities and Exchange Commission filing
5/22/17 - Adamas Pharmaceuticals Inc. Files SEC Form 8-K, Current Report (May. 9, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Adamas Pharmaceuticals Inc. was posted on May 9, 2017. The SEC file number is 0001628280-17-005238.. A U.S. Securities and Exchange Commission filing
5/22/17 - Adamas Presents Positive Phase 1a Data of ADS-4101 (lacosamide) for the Treatment of Partial Onset Seizures in Epilepsy
Adamas Pharmaceuticals, Inc. today announced a presentation of positive data from the Phase 1 a clinical trial of ADS-4101 modified-release capsules, in a podium presentation at the 14 th Antiepileptic Drug and Device Trials Conference. We have successfully confirmed our hypothesis that the rapid initial rise in blood levels contributes to the
5/22/17 - Aeterna Zentaris Inc. Files SEC Form 6-K, Report of Foreign Issuer [Rules 13A-16 And 15D-16] (May. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Aeterna Zentaris Inc. was posted on May 8, 2017. The SEC file number is 0001113423-17-000015.. A U.S. Securities and Exchange Commission filing is a
5/22/17 - Aferetica and CytoSorbents Extend Exclusive "Life-saving" Partnership through 2021
MIRANDOLA, Italy and MONMOUTH JUNCTION, N.J., May 22, 2017/ PRNewswire/ Aferetica srl, an innovative start-up specializing in blood purification, and CytoSorbents Corporation, a critical care immunotherapy leader commercializing CytoSorb to treat deadly inflammation, announced the renewal of their partnership enabling Aferetica to exclusively.
5/22/17 - Agile Therapeutics Inc. Files SEC Form 10-Q, Quarterly Report [Sections 13 Or 15(D)] (May. 8, 2017)
By a News Reporter-Staff News Editor at Pharma Business Week According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission filing by Agile Therapeutics Inc. was posted on May 8, 2017. The SEC file number is 0001104659-17-030669.. A U.S. Securities and Exchange Commission filing is
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415